For instance, the sodium–glucose cotransporter 2 inhibitor empagliflozin, which is also used for the treatment of type 2 diabetes, did not change serum galectin-3 levels within 20 weeks of therapy [183]. The gene discussed is LGALS3; the disease is type 2 diabetes mellitus.